课题基金 / 基金详情

DOSE RESPONSE EVALUATION OF ORAL ILLOPROSE IN SEVERE PAOD

DOSE RESPONSE EVALUATION OF ORAL ILLOPROSE IN SEVERE PAOD
口服伊洛普糖治疗重度 PAOD 的剂量反应评估
批准号：
6116955
负责人：
JOHN M PORTER
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116955
关键词：
artery occlusion cardiovascular disorder chemotherapy clinical research clinical trials dosage drug screening /evaluation human subject human therapy evaluation iloprost oral administration prostacyclins

项目摘要

项目成果

JOHN M PORTER的其他基金

相关文献

中文摘要
翻译
前列环素类似物（伊洛前列素等）已用于 治疗外周动脉闭塞性疾病（PAOD）， 年 最近的研究证明了静脉注射以及 口服伊洛前列素治疗缺血性溃疡和缺血性静息痛， 为一项双盲、安慰剂对照研究奠定基础， 口服伊洛前列素治疗重度前列腺增生症安全性和有效性 PAOD。
英文摘要
Prostacyclin analogs (Iloprost, and others) have been used in the treatment of peripheral arterial occlusive disease (PAOD) for several years. Recent studies have documented benefit from intravenous as well as oral Iloprost in the treatment of ischemic ulcers and ischemic rest pain, setting the stage for a double-blind, placebo-controlled study to evaluate the safety and efficacy of oral Iloprost therapy in patients with severe PAOD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA
DOSE RESPONSE EVALUATION OF ILOPROST IN TREATMENT OF CLAUDICATION
INTRAVENOUS AS 013 FOR TREATMENT OF SEVERE LIMB ISCHEMIA